Published Research and Presentations

P3 BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs) (TPS5102)

P3BEP

2023 ASCO Annual Meeting

02/06/2023

DS Zebic, B Tran, AJ Martin, FD Pashankar, D Mazhar, RA Huddart, M Wheater, ET Walpole, E Dunwoodie, DR Feldman, AJ Birtle, D Wyld, NJ Lawrence, MR Stockler, PS Grimison on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Adding mitomycin (MM) to Bacillus Calmette-Guérin (BCG) as adjuvant intravesical therapy for high-risk, non muscle-invasive urothelial bladder cancer (NMIBC) (BCGMM; ANZUP 1301)

BCG+MM

2023 ASCO Annual Meeting

02/06/2023

D Hayne, MR Stockler, AJ Martin, S McCombie, DS Zebic, PA Bastick, EK Beardsley, M Frydenberg, W Green, J Grummet, C Hawks, J Ischia, A Mitterdorfer, M Patel, M Roberts, S Sengupta, RK Srivastav, AD Redfern, ID Davis, on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

E: A randomized non-comparative phase II trial of biomarker driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903)

GUIDE

2023 ASCO Annual Meeting

02/06/2023

Ciara Conduit, Blossom Mak, Wenjia Qu, Juliana Di lulio, Ronan Burder, Matthias Bressel, Thomas Cusick, Haryana M Dhillon, Richard De Abreu Lourenço, Craig Underhill, Javier Torres, Megan Crumbaker, Florian Honeyball, Anthony Linton, Sanjeev Sewak, Ray Allen1, Ian D Davis, Susan J Clark, Lisa G Horvath, *, Kate L Mahon, * on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

Adding Mitomycin to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasivebladder cancer: a randomised phase 3 trial: The BCG+MM Trial (ANZUP 1301)

BCG+MM

EAU 23

10/03/2023

Hayne D., Stockler M., Martin A.J., Mccombie S., Zebic D., Krieger L., Anderson P., Bastick P., Beardsley E., Blatt A., Frydenberg M., Green W., Grummet J., Hawks C., Ischia J., Mitterdorfer A., Patel M., Roberts M., Sengupta S., Srivastav R., Winter M., Redfern A.D., Davis I.D.

EVOLUTION: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (ANZUP 2001

EVOLUTION

22/02/2023

Shahneen Sandhu, Shalini Subramaniam Michaels. Kolman. Marfin R. Stockler, Andrew James Martin. Izabella Pokorski Jeffrey C Goh. David A. Pallison. Nattakom Ohiantravan• Craig Gedye Natalie K. Ruthefford Anthony M. Joshua Thean Hsiang Tan'. Ian o. Kirkwood'. Sze Ting Lee, Andrew J. Weickhardt, Ramin Alipaur1, Andrew Nguyen, Ian Davis, Louise Emmett,

Abstract 372: Societal benefits of surrogate outcomes to support reimbursement decisions: the case of prostate cancer

Other

22/02/2023

Rafael Emilio de Feria Cardet, Stephen Goodall, Tracey-Lea Laba, Marion Haas, Ian D. Davis, Richard De Abreu Lourenço.

Abstract #394646: Trial in Progress – Primary retroperitoneal lymph node dissection for clinical stage II testicular germ cell tumour and its impact on health-related quality of life compared to chemotherapy or radiotherapy (PRESTIGE)

Other

22/02/2023

Ciara Conduit, Jeremy Lewin, Elizabeth C Liow, Haryana Dhillon, Wei Hong, Richard De Abreu Lourenco, Nathan Lawrentschuk, Benjamin Thomas, Peter Grimison, Shomik Sengupta, Ben Tran

Abstract #393644: Trial in Progress – Exploring the activity of pseudoephedrine in treating retrograde ejaculation following RPLND in survivors of testicular cancer (PREPARE)

Other

22/02/2023

Ciara Conduit, Jeremy Lewin, Ie-Wen Sim, Haryana Dhillon, Wei Hong, Amanda Hutchinson, Gulfam Ahmad, Nathan Lawrentschuk, Benjamin Thomas, Matt Leonard, Ben Tran

An international r andomi z ed phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours: P3BEP (ANZUP protocol 1302)

P3BEP

22/02/2023

DZebic, M Stockler A Martin F Pashankar, B Tran D Mazhar, R Huddart, M Wheater, E Walpole, E Dunwoodie, DR Feldman, A Birtle AG Stevanovic, D Wyld, FJ Hanning, P SGrimison

DASL-HiCaP: Darolutamide Augments Standard therapy for Localized very High-risk Cancer of the Prostate – a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically localized prostate cancer (ANZUP 1801

DASL-HiCaP

22/02/2023

T Niazi SM McBride, S Williams, ID Davis, MR Stockler AJ Martin, HT Chung, FT Roncolato, A Ebacher, E Khoo, J Martin, TS Lim, S Hughes, D Pryor, J Catto, P Kelly, LG Rezaei, SC Morgan, R Rendon, CJ Sweeney